FDA
-
-
-
-
-
-
-
BeOne Medicines’ BEQALZI™ (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphoma
-
-
-
-
-
-
-
BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma
-
-
-
-
-
-
-
BeOne Medicines’ Sonrotoclax Granted Breakthrough Therapy Designation by U.S. FDA
-
-
-
-
-
-
-
U.S. FDA Approves Tablet Formulation of BeOne’s BRUKINSA® for All Approved Indications
-
-
-
-
-
-
-
TEVIMBRA Approved in U.S. for First-line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination with Chemotherapy
-
-
-
-
-
-
-
BeiGene Enters Next Phase of Global Growth with Announcement of Second Quarter 2024 Financial Results and Corporate Updates
-
-
-
-
-
-
-
BeiGene Announces FDA Accelerated Approval of BRUKINSA for the Treatment of Relapsed or Refractory Follicular Lymphoma
-
323,580 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

